What is the recommended dosing, monitoring, and contraindications for abiraterone acetate in a patient with metastatic castration‑resistant prostate cancer receiving continuous androgen‑deprivation therapy?

Abiraterone Dosing and Management in Metastatic Castration-Resistant Prostate Cancer

For patients with metastatic castration-resistant prostate cancer (mCRPC) on continuous androgen-deprivation therapy (ADT), abiraterone acetate should be dosed at 1,000 mg orally once daily on an empty stomach (no food 2 hours before and 1 hour after) combined with prednisone 5 mg orally twice daily, with continuation of ADT via GnRH analog or prior bilateral orchiectomy. 1

Standard Dosing Regimen

The FDA-approved dosing for mCRPC is:

• Abiraterone acetate: 1,000 mg (two 500 mg tablets or four 250 mg tablets) once daily
• Prednisone: 5 mg orally twice daily
• Administration: On an empty stomach (fasting state mandatory)
• Concurrent ADT: Must continue GnRH analog or have had bilateral orchiectomy 1

The tablets must be swallowed whole with water—do not crush or chew 1.

Alternative Dosing Options

Cost-Saving Alternative

250 mg daily with a low-fat breakfast can be considered as an alternative to the standard 1,000 mg fasting dose for patients who cannot afford or will not adhere to the standard regimen 2. While a recent 2026 trial showed comparable PSA responses and survival outcomes with this low-dose approach 3, this remains off-label and the NCCN guidelines note this may reduce financial toxicity and improve adherence 2.

Fine-Particle Formulation

500 mg daily of the fine-particle formulation with methylprednisolone 4 mg orally twice daily is FDA-approved and bioequivalent to standard dosing 2. This is NCCN category 2A 2.

Critical Monitoring Requirements

Hepatic Function Monitoring

Monitor ALT, AST, and bilirubin:

• Baseline: Before treatment initiation
• First month: Every 2 weeks
• Months 2-3: Monthly
• Thereafter: Monthly 1

This intensive monitoring is essential because grade 3-5 liver toxicity occurs in approximately 7% of patients 2.

Additional Monitoring Parameters

• Blood pressure: Regularly (severe hypertension occurs in 10% of patients) 2
• Serum potassium: Frequently during early treatment (hypokalemia in 17%) 2
• Renal function: Regular monitoring 2
• Testosterone levels: Document castrate levels (<50 ng/dL) if clinically indicated 2

Dose Modifications for Hepatotoxicity

During Treatment Hepatotoxicity

If ALT/AST >5× ULN or total bilirubin >3× ULN develops:

1. Interrupt abiraterone immediately 1
2. Resume at 750 mg once daily when LFTs return to baseline or AST/ALT ≤2.5× ULN and bilirubin ≤1.5× ULN
3. Monitor: Every 2 weeks for 3 months, then monthly
4. If recurs at 750 mg: Reduce to 500 mg once daily (same LFT criteria for restart)
5. If recurs at 500 mg: Permanently discontinue 1

Hy's Law Criteria

Permanently discontinue immediately if concurrent ALT >3× ULN and total bilirubin >2× ULN occur without biliary obstruction 1.

Baseline Hepatic Impairment

• Moderate impairment (Child-Pugh B): Reduce dose to 250 mg once daily with intensive monitoring (weekly for first month, every 2 weeks for next 2 months, then monthly) 1
• Severe impairment (Child-Pugh C): Absolute contraindication—do not use 1

Contraindications

Absolute contraindications:

• Severe hepatic impairment (Child-Pugh Class C) 1
• Pregnancy (not applicable in this male population)

Relative contraindications requiring careful consideration:

• Baseline moderate hepatic impairment (requires dose reduction)
• Uncontrolled hypertension (manage before initiating)
• Significant cardiac disease (cardiac disorders occur in 19%, serious in 6%) 2
• Age ≥70 years with significant comorbidities (increased toxicity: 47% vs 33% grade 3-5 adverse events, with 9 vs 3 treatment-related deaths in STAMPEDE) 2

Concomitant Medications

Continue bone-protective therapy with denosumab (category 1, preferred) or zoledronic acid if bone metastases present 2.

Manage mineralocorticoid excess (hypertension, hypokalemia, edema) with the coadministered prednisone; if inadequate, consider adding eplerenone or other mineralocorticoid antagonist 4, 5.

Common Pitfalls to Avoid

1. Food interaction: Emphasize strict fasting requirements—food dramatically increases absorption unpredictably and can lead to toxicity 2, 1
2. Inadequate hepatic monitoring: The intensive early monitoring schedule is not optional—7% develop grade 3-5 liver toxicity 2
3. Stopping ADT: While recent data suggest abiraterone alone may maintain castrate testosterone levels in 94.6% of patients 6, current FDA labeling and guidelines mandate continuation of ADT 1
4. Age-related toxicity: Patients ≥70 years have substantially higher toxicity rates and may have reduced benefit (HR 0.94 vs 0.51 in younger patients) 2
5. Inadequate blood pressure control: 10% develop severe hypertension or cardiac disorders—proactive management is essential 2

Role in Treatment Sequence

In the mCRPC setting, abiraterone is a category 1, preferred option for patients without prior androgen receptor pathway inhibitor (ARPI) therapy 2. However, current 2025 ASCO guidelines indicate that after progression on both an ARPI and docetaxel, other options (177Lu-PSMA-617 for PSMA-positive disease, olaparib for HRR mutations, cabazitaxel) are generally preferred over switching to a second ARPI 7.